Cordance Medical awarded Phase II National Science Foundation Award

$1M of non-dilutive capital awarded to advance product development of its novel blood-brain barrier drug delivery device for neurology diseases

Mountain View, Calif. – Cordance Medical has received a $1M phase II award from the National Science Foundation (NSF) entitled “Transcranial Dynamic Focused Ultrasound for the Non-Invasive Opening of the Blood-Brain Barrier (BBB).”   

“The NSF award will help us continue our pursuit of improving drug delivery to the brain,” said Bhaskar Ramamurthy Ph.D., founder, and CTO at Cordance Medical. “We are incredibly excited to continue our partnership with the NSF in our pursuit to make a non-invasive BBB penetrant device.”

As part of the award, Cordance will set up translational studies to utilize the non-invasive and portable device in large animals to demonstrate the safety and efficacy of BBB opening.  The Cordance device leverages focused ultrasound device in a novel product design that could enable a globally scalable device after development. The NSF award is funded through the Small Business Innovation Research (SBIR) Program and follows upon an earlier $250k phase I award received in 2019.